[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366960-105":59,"doc-detail-366960-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","mrpl17-is-a-critical-regulator-of-mitochondrial-function-and-a-novel-therapeutic-target-in-non-small-cell-lung-cancer","MRPL17 is a critical regulator of mitochondrial function and a novel therapeutic target in non-small cell lung cancer","","Study of the mitochondrial protein MRPL17 (mitochondrial ribosomal protein L17) in non-small cell lung cancer (NSCLC) identifies a pro-cancer regulatory role. Transcriptomic analyses show MRPL17 upregulation in LUAD and LUSC tumors, with higher expression linked to advanced stage, lymph node metastasis, and worse overall survival. MRPL17 silencing or knockout reduces NSCLC viability, proliferation, migration, and invasion while inducing apoptosis by impairing mitochondrial respiration and ATP production, partly rescuable by antioxidants or glucose. MRPL17 overexpression enhances aggressive phenotypes and mitochondrial output. COX8A is confirmed as a direct downstream mediator, and MRPL17 knockdown suppresses xenograft growth in mice alongside COX8A reduction, mitochondrial dysfunction, oxidative stress, and apoptosis.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mrpl17-is-a-critical-regulator-of-mitochondrial-function-and-a-novel-therapeutic-target-in-non-small-cell-lung-cancer/366960/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mrpl17-is-a-critical-regulator-of-mitochondrial-function-and-a-novel-therapeutic-target-in-non-small-cell-lung-cancer/366960.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main biological focus of the study?","Question",{"text":112,"@type":113},"The study focuses on MRPL17, a mitochondrial protein, and how it regulates mitochondrial function in non-small cell lung cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is MRPL17 expression linked to clinical outcomes in NSCLC?",{"text":117,"@type":113},"MRPL17 is upregulated in LUAD and LUSC tumor tissues, and elevated levels correlate with advanced disease stage, positive lymph node metastasis, and poorer overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"What happens to NSCLC cells when MRPL17 is silenced or knocked out?",{"text":121,"@type":113},"Silencing or knockout of MRPL17 reduces cell viability, proliferation, migration, and invasion while promoting apoptosis.",{"name":123,"@type":110,"acceptedAnswer":124},"How does MRPL17 exert its pro-cancer effects and what mediator is identified?",{"text":125,"@type":113},"Mechanistically, MRPL17 disruption impairs mitochondrial respiratory function and cellular redox balance; COX8A is identified as a direct downstream target mediating its pro-cancerous effects.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},366960,1790195535,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nMRPL17 is a critical regulator of mitochondrial function and a novel therapeutic target in non-small cell lung cancer  \nChuanyong Mu1,6, Jun-gang Zhao2,6, Yonghua Sang 3 ✉, Yu-bo Yan4 ✉ and Ming Liu5 ✉  \n© The Author(s) 2025  \n\n|  |  |  |\n| --- | --- | --- |\n|  | This study investigated the role of the mitochondrial protein MRPL17 (mitochondrial ribosomal protein L17) in non-small cell lung cancer (NSCLC), exploring its expression proﬁle, clinical signiﬁcance, and therapeutic potential. Transcriptomic analyses of TCGA and single-cell RNA sequencing data revealed signiﬁcant upregulation of MRPL17 in LUAD (lung adenocarcinoma) and LUSC (lungsquamous cell carcinoma) tumor tissues, particularly within malignant epithelial and proliferating cancer cells. Elevated MRPL17 expression correlated with advanced stages, positive lymph node metastasis, and poorer overall survival. In vitro investigations demonstrated that silencing or knockout of MRPL17 attenuated cell viability, proliferation, migration, and invasion in NSCLC cells, while promoting apoptosis. Mechanistically, MRPL17 silencing impaired mitochondrial respiratory function, causing reduced oxygen consumption, diminished Complex I activity, and decreased ATP. These impairments were partially reversible by antioxidant treatment or glucose supplementation. Conversely, MRPL17 overexpression enhanced aggressive cellular phenotypes and mitochondrial energetic output. Bioinformatic analysis and subsequent experiments conﬁrmed COX8A as a direct downstream target of MRPL17, mediating its pro-cancerous effects. In vivo, MRPL17 silencing suppressed NSCLC xenograft growth in nude mice, a phenomenon associated with reduced COX8A levels, mitochondrial dysfunction, heightened oxidative stress, and increased apoptosis. Thus, MRPL17 is an important pro-cancerous target in NSCLC, driving malignant progression through the regulation of |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | mitochondrial function and cellular redox balance, with COX8A identiﬁed as a key mediator. |  |\n|  |  |  |\n|  |  |  |\n|  | Cell Death and Disease (2026)17:105; [https://doi.org/10.1038/s41419-025-08343-z](https://doi.org/10.1038/s41419-025-08343-z) |  |\n|  |  |  |\n\nINTRODUCTION  \nNon-small cell lung cancer (NSCLC) stands as the predominant form of lung malignancy, representing ~85% of all pulmonary carcinoma diagnoses [1] . Globally, it remains a leading cause of cancer-related mortality [2, 3], with a grim 5-year overall survival rate for advanced stages typically remaining below 20%[1] . While standard treatment modalities like surgical resection, radiation therapy, and cytotoxic chemotherapy offer some beneﬁts, asigniﬁcant portion of patients face disease recurrence or progression [4]. The inherent limitations of these conventional treatments, particularly their considerable systemic toxicities and the widespread development of acquired chemoresistance, urgently highlight the need for more precise and effective therapeutic interventions [1, 4, 5] .  \nThe therapeutic landscape for NSCLC has markedly evolved with the advent of molecularly targeted therapies and immunotherapies [5–8] . Agents such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) [9], anaplastic lymphoma kinase (ALK) inhibitors [10], and programmed cell death protein 1 (PD-1)/ligand 1 (PD-L1) checkpoint inhibitors [11] have demonstrated substantial clinical beneﬁts, including improved survival and higher objective response rates in  \npatients with speciﬁc genomic alterations or relevant immune checkpoint expression [5–8] . However, the efﬁcacy of these targeted approaches is frequently curtailed by the inevitable emergence of acquired resistance mechanisms (e.g., EGFR T790M mutation, ALK fusion gene rearrangements) and the intrinsic heterogeneity of tumor bi","cbCaiqZy4ESi8DmX","https://ap.wps.com/l/cbCaiqZy4ESi8DmX","pdf",6099844,17,"English","# Introduction\n## NSCLC clinical burden and current therapies\n## Targeted therapy and immunotherapy challenges\n## Mitochondrial hyperfunction in cancer and therapeutic rationale","[{\"question\":\"What is the main biological focus of the study?\",\"answer\":\"The study focuses on MRPL17, a mitochondrial protein, and how it regulates mitochondrial function in non-small cell lung cancer.\"},{\"question\":\"How is MRPL17 expression linked to clinical outcomes in NSCLC?\",\"answer\":\"MRPL17 is upregulated in LUAD and LUSC tumor tissues, and elevated levels correlate with advanced disease stage, positive lymph node metastasis, and poorer overall survival.\"},{\"question\":\"What happens to NSCLC cells when MRPL17 is silenced or knocked out?\",\"answer\":\"Silencing or knockout of MRPL17 reduces cell viability, proliferation, migration, and invasion while promoting apoptosis.\"},{\"question\":\"How does MRPL17 exert its pro-cancer effects and what mediator is identified?\",\"answer\":\"Mechanistically, MRPL17 disruption impairs mitochondrial respiratory function and cellular redox balance; COX8A is identified as a direct downstream target mediating its pro-cancerous effects.\"}]","MRPL17 is a critical regulator of mitochondrial function and a novel therapeutic target in non-small cell lung cancer | PDF",1790168411,43,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13bfe181e3b83dde45802e09ea8cddab.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3fae87888d569d42bb7f2dc5d9278c32.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/370f8001d43484c6cc563a2ed6423bbb.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfad18e136d66bb4ada90b3409b724ab.webp",980,1301]